Breast Cancer Follow-Up and Surveillance After Primary Treatment: ASCO Guideline Update

Z Zeina Nahleh C Catherine M. Alfano (Northwell Health, New Hyde Park, New York, NY) M Mark R. Somerfield (American Society of Clinical Oncology, Alexandria, VA) J Janie M. Lee (Fred Hutchinson Cancer Center, Seattle, WA) T Tina J. Hieken (Mayo Clinic, Rochester, MN) A Allison Magnuson (University of Rochester Medical Center, Rochester, NY) R Ruta D. Rao (Rush University Cancer Center, Chicago, IL) H Helen K. Chew (UC Davis Comprehensive Cancer Center, Sacramento, CA) S Stephen K. L. Chia (Division of Medical Oncology, Vancouver Cancer Centre, Vancouver, BC, Canada) B Brittany E. Harvey (American Society of Clinical Oncology, Alexandria, VA) E Ellen Landsberger (New York City, NY) B Bora Lim S Sitna Ali Mwanzi (Kenyatta National Hospital, Nairobi, Kenya) H Heather A. Parsons D Debra Patt (Texas Oncology, Austin, TX) J Jasmine S. Sukumar (MD Anderson Cancer Center, Houston, TX) H Hyuna Sung (Cancer Surveillance Research American Cancer Society Atlanta Georgia USA) G Gustavo Werutsky (Latin American Cooperative Oncology Group, Porto Alegre, Brazil) M Maryam Lustberg (Yale Cancer Center, New Haven, CT)

Abstract

PURPOSE To offer clinicians recommendations concerning breast cancer follow-up and surveillance after primary treatment. METHODS ASCO convened an Expert Panel to develop recommendations based on a systematic review and a formal consensus process. RESULTS One randomized controlled trial (RCT) was identified and formed the evidentiary basis for the surveillance mammography guideline recommendation. No RCTs were identified that evaluated different follow-up approaches by risk of relapse in patients treated for early-stage breast cancer. Given the dearth of evidence identified in the systematic review of the literature, formal modified Delphi consensus-based recommendations were generated. RECOMMENDATIONS The guideline offers recommendations on the role of a risk-based approach to the frequency and intensity of follow-up among patients with breast cancer in the adjuvant setting. Regular history, physical examination, and mammography are recommended for breast cancer follow-up. Either virtual or in-person visits can be offered. Certain patients at high risk of cancer recurrence warrant closer surveillance, such as those patients with locally advanced disease or residual disease following neoadjuvant chemotherapy. Recommendations on the use of blood-based biomarkers and supplemental imaging are provided. Guideline recommendations will be updated once additional evidence-based tools become available to better individualize surveillance. Additional information is available at www.ascopubs.org/topics/asco-guidelines/breast-cancer .

Article Details

Volume / Issue Vol. 1, Issue 1
Published July 16, 2026
ISSN 0732-183X
Publisher Lippincott Williams & Wilkins

Journal Info

Journal of Clinical Oncology

Lippincott Williams & Wilkins

ISSN: 0732-183X Health Sciences

Authors (19)

Z

Zeina Nahleh

C

Catherine M. Alfano

Northwell Health, New Hyde Park, New York, NY

M

Mark R. Somerfield

American Society of Clinical Oncology, Alexandria, VA

J

Janie M. Lee

Fred Hutchinson Cancer Center, Seattle, WA

T

Tina J. Hieken

Mayo Clinic, Rochester, MN

A

Allison Magnuson

University of Rochester Medical Center, Rochester, NY

R

Ruta D. Rao

Rush University Cancer Center, Chicago, IL

H

Helen K. Chew

UC Davis Comprehensive Cancer Center, Sacramento, CA

S

Stephen K. L. Chia

Division of Medical Oncology, Vancouver Cancer Centre, Vancouver, BC, Canada

B

Brittany E. Harvey

American Society of Clinical Oncology, Alexandria, VA

E

Ellen Landsberger

New York City, NY

B

Bora Lim

S

Sitna Ali Mwanzi

Kenyatta National Hospital, Nairobi, Kenya

H

Heather A. Parsons

D

Debra Patt

Texas Oncology, Austin, TX

J

Jasmine S. Sukumar

MD Anderson Cancer Center, Houston, TX

H

Hyuna Sung

Cancer Surveillance Research American Cancer Society Atlanta Georgia USA

G

Gustavo Werutsky

Latin American Cooperative Oncology Group, Porto Alegre, Brazil

M

Maryam Lustberg

Yale Cancer Center, New Haven, CT